Cargando…
Signaling Mechanisms that Suppress the Cytostatic Actions of Rapamycin
While rapamycin and the “rapalogs” Everolimus and Temsirolimus have been approved for clinical use in the treatment of a number of forms of cancer, they have not met overarching success. Some tumors are largely refractory to rapamycin treatment, with some even undergoing an increase in growth rates....
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057458/ https://www.ncbi.nlm.nih.gov/pubmed/24927123 http://dx.doi.org/10.1371/journal.pone.0099927 |